Opinion|Videos|April 11, 2025
Hepatic Safety of IL-17 Inhibitors in Patients With Psoriasis
Panelists discuss how when prescribing an IL-17 inhibitor, key safety considerations include infection risk (particularly tuberculosis and fungal infections), inflammatory bowel disease exacerbation, allergic reactions, neutropenia, immunogenicity, vaccination timing, pregnancy/breastfeeding status, malignancy history, and monitoring requirements for adverse events.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What safety data do you take into consideration when prescribing an IL-17 inhibitor?
Advertisement
Related to this article
BE BOLD Week 24 data show sustained numerical advantages in joint responses with bimekizumab versus risankizumab in active psoriatic arthritis.
Doral Fredericks, PharmD, MBA, discusses how life stages, mental health, and reproductive concerns can shape dermatologic care for women.
The approval expands the IL-23 inhibitor’s indications beyond moderate-to-severe plaque psoriasis to include adults with active psoriatic arthritis.
Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.
Experts outline how to recognize undertreated psoriasis, assess incomplete response, and make individualized decisions when escalating therapy.
ORKA-001 achieved PASI 100 in 61% of high-dose patients at week 16 in the phase 2b EVERLAST-B trial of moderate-to-severe psoriasis.
Tina Bhutani-Jacques, MD, explored how disease location, prior treatment response, and patient preference shape topical treatment decisions across 3 plaque psoriasis cases.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
Advertisement
Advertisement
Trending on Dermatology Times
1
Don't Be Rash: Navigating Topical Steroid Withdrawal Concerns in Pediatric Eczema
2
AADA Warns of 6% Medicare Payment Cut for Dermatologists in 2027
3
ATTO-1310 Reduces Itch at Week 12 in Chronic Pruritus and Atopic Dermatitis
4
Where Patients With Alopecia Areata Fit on the Path to Systemic Treatment
5